You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A novel multiple-stage antimalarial agent that inhibits protein synthesis
|
|---|---|
| Published in |
Nature, June 2015
|
| DOI | 10.1038/nature14451 |
| Pubmed ID | |
| Authors |
Beatriz Baragaña, Irene Hallyburton, Marcus C. S. Lee, Neil R. Norcross, Raffaella Grimaldi, Thomas D. Otto, William R. Proto, Andrew M. Blagborough, Stephan Meister, Grennady Wirjanata, Andrea Ruecker, Leanna M. Upton, Tara S. Abraham, Mariana J. Almeida, Anupam Pradhan, Achim Porzelle, María Santos Martínez, Judith M. Bolscher, Andrew Woodland, Torsten Luksch, Suzanne Norval, Fabio Zuccotto, John Thomas, Frederick Simeons, Laste Stojanovski, Maria Osuna-Cabello, Paddy M. Brock, Tom S. Churcher, Katarzyna A. Sala, Sara E. Zakutansky, María Belén Jiménez-Díaz, Laura Maria Sanz, Jennifer Riley, Rajshekhar Basak, Michael Campbell, Vicky M. Avery, Robert W. Sauerwein, Koen J. Dechering, Rintis Noviyanti, Brice Campo, Julie A. Frearson, Iñigo Angulo-Barturen, Santiago Ferrer-Bazaga, Francisco Javier Gamo, Paul G. Wyatt, Didier Leroy, Peter Siegl, Michael J. Delves, Dennis E. Kyle, Sergio Wittlin, Jutta Marfurt, Ric N. Price, Robert E. Sinden, Elizabeth A. Winzeler, Susan A. Charman, Lidiya Bebrevska, David W. Gray, Simon Campbell, Alan H. Fairlamb, Paul A. Willis, Julian C. Rayner, David A. Fidock, Kevin D. Read, Ian H. Gilbert |
| Abstract |
There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery. |
X Demographics
The data shown below were collected from the profiles of 200 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 34 | 17% |
| United States | 23 | 12% |
| Australia | 9 | 5% |
| Germany | 7 | 4% |
| Nigeria | 5 | 3% |
| Japan | 4 | 2% |
| Spain | 4 | 2% |
| Brazil | 4 | 2% |
| Switzerland | 3 | 2% |
| Other | 20 | 10% |
| Unknown | 87 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 135 | 68% |
| Scientists | 53 | 27% |
| Science communicators (journalists, bloggers, editors) | 6 | 3% |
| Practitioners (doctors, other healthcare professionals) | 5 | 3% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 569 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | <1% |
| Portugal | 2 | <1% |
| Germany | 2 | <1% |
| Malaysia | 1 | <1% |
| France | 1 | <1% |
| Vietnam | 1 | <1% |
| India | 1 | <1% |
| Canada | 1 | <1% |
| Argentina | 1 | <1% |
| Other | 4 | <1% |
| Unknown | 550 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 125 | 22% |
| Researcher | 111 | 20% |
| Student > Master | 80 | 14% |
| Student > Bachelor | 48 | 8% |
| Other | 30 | 5% |
| Other | 80 | 14% |
| Unknown | 95 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 145 | 25% |
| Chemistry | 105 | 18% |
| Biochemistry, Genetics and Molecular Biology | 79 | 14% |
| Medicine and Dentistry | 34 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 32 | 6% |
| Other | 59 | 10% |
| Unknown | 115 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 372. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2023.
All research outputs
#85,560
of 25,654,806 outputs
Outputs from Nature
#6,119
of 98,462 outputs
Outputs of similar age
#770
of 278,243 outputs
Outputs of similar age from Nature
#111
of 995 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 98,462 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 102.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,243 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 995 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.